OmniAb, Inc.
OmniAb, Inc.
Your view on OABIW
Overview
What the company does, where it operates, and who runs it.
About OmniAb, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Matthew W. Foehr
- Headquarters
- 5980 Horton Street, EmeryVille, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Matthew W. Foehr
- Headquarters
- 5980 Horton Street, EmeryVille, CA, US
OmniAb, Inc., established in 2012 and headquartered in Emeryville, California, operates as a biotechnology firm focused on pioneering technologies for the discovery of therapeutic antibodies within the United States.
The company's flagship offering is its OmniAb platform, which provides industry collaborators with access to a broad spectrum of antibody repertoires and advanced screening techniques. This capability empowers partners to develop next-generation therapeutic agents.
At the heart of the OmniAb platform are proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse. These animals have been genetically engineered to produce antibodies featuring human sequences, thereby streamlining the path to creating human therapeutic candidates.
Beyond this core offering, OmniAb also addresses specific industry needs with specialized animal models: OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken) facilitate bispecific antibody applications through a shared light chain mechanism.
Additionally, OmniTaur provides a solution for challenging targets by leveraging the distinctive structural characteristics of cow antibodies.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for OmniAb, Inc. from FRC's valuation model, read against the market price. OABIW last traded at $0.42; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for OmniAb, Inc.. Starting points for OmniAb, Inc.: EPS -$0.34, beta 1.22 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for OmniAb, Inc.. OmniAb, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for OmniAb, Inc.. Trailing twelve-month EPS for OmniAb, Inc. stands at -$0.34. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.12 | -$0.10 | -$0.35 | -$0.26 |
| Low estimate | -$0.17 | -$0.13 | -$0.49 | -$0.36 |
| High estimate | -$0.07 | -$0.06 | -$0.28 | -$0.21 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | -$0.11 | -$0.06 | -$0.57 | — |
| Growth | -10.4% | -58.3% | +39.3% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $5.20M | $7.38M | $36.93M | $46.99M |
| Low estimate | $3.70M | $5.03M | $35.40M | $36.45M |
| High estimate | $6.56M | $9.73M | $38.25M | $72.00M |
| No. of analysts | 7 | 2 | 7 | 6 |
| Year-ago revenue | $8.38M | $14.40M | $18.67M | — |
| Growth | -37.9% | -48.8% | +97.8% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 13, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for OmniAb, Inc.. OmniAb, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
OmniAb, Inc. valued side by side against its closest peers. OmniAb, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold OmniAb, Inc., and how their positions are changing. At a $726.4M market value, institutional positions materially move OmniAb, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by OmniAb, Inc. executives and directors. Shares of OmniAb, Inc. have traded between $0.06 and $0.17 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for OmniAb, Inc.. Coverage tracks OmniAb, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of OmniAb, Inc.